October 2, 2009
By:Timothy Pratt, PhD
Reimbursement in Clinical Trials is a perennial source of concern for both payors and payees. Failure to reimburse appropriately can negatively impact otherwise cordial Sponsor-Site relations; appropriate goes well beyond a determination of "Fair Market Value", however, and extends to timely and reliable payments, with clear and transparent reporting for troubleshooting and Regulatory compliance. In many instances, attempting to provide appropriate reimbursement can prove problematic and a high burden of work. This paper examines how the Clinical Reimbursement process can be greatly improved via the use of eClinical technologies, outlines assessment metrics for the utility of reimbursement systems, and examines a current example of a quality system ranked using those specified metrics.
 |
September 1, 2009
By:SAS
Knowing that a physician has been a high prescriber in the past is no longer enough information to set you apart from the competition. Using advanced analytics in-house can help you predict outcomes of promotions and lead to more focused marketing ? without having to rely on outside consultants. The paper includes case studies of several companies, including one that boosted earnings by $27 million over four months and another that saw a 19 percent gain in prescribing.
|
July 17, 2009
By:Richard Tieken, Timothy Pratt, PhD
Non-digital data recording mechanisms have existed for millennia, and due to the inherent nature of the media have produced a distinctly linear thought pattern in most activities including clinical research management. Digital data recording methods, however, open up a broad range of possibilities for data access and capture to operate on a distinctly non-linear fashion. This whitepaper explores what may be achieved with the appropriate Vision, specifically with respect to Trial Master Files and Document Management.
|
July 17, 2009
By:SAS
This white paper shows how to develop, execute and manage the transformation, analysis and submission of clinical research data with SAS® Drug Development. It includes an executive summary that outlines current industry challenges. And, it answers the top ten questions life sciences executives confront when trying to balance innovation with regulatory compliance.
|
April 8, 2009
Concise Executive Guide to Business Analytics: Overview of business applications and payoffs, staff and technology requirements, and the roles executives must play to realize the performance potential of analytics. Six key questions are asked about how well information at hand is used to meet goals and innovate in the marketplace.
|
April 1, 2009
By:SAS
This white paper shows how to develop, execute and manage the transformation, analysis and submission of clinical research data with SAS® Drug Development. It includes an executive summary that outlines current industry challenges. And, it answers the top ten questions life sciences executives confront when trying to balance innovation with regulatory compliance.
|
April 1, 2009
By:SAS
Information technology is finally up to the task of cost-effective clinical research. But there are still some significant barriers to gaining all the benefits of the technology, in particular, interoperability. This white paper explores the need for a consistent industry architecture that allows life sciences firms to connect their enterprises and benefit from unified data integration, process consistency and rapid communication of meaningful drug findings.
|
August 8, 2007
In today's clinical trial landscape, a global footprint is instrumental in achieving full patient enrollment and on-time schedules. This White Paper includes 10 Tips for Feasibility Success and a Sample Feasibility Study Questionnaire.
|
June 13, 2007
This issue is an attempt to present the entire picture of the Russian market of clinical trials as of early 2007. It provides general information related to clinical trials in Russia, survey of the current legal basis, analysis of clinical trials being currently conducted in Russia by sponsors, phases and therapeutic fields, rating of the most active foreign and Russian drug developers, review of services and rating of contract research organizations available in Russia and investigative sites.
|
| 
